Rosetta Genomics

Rosetta Genomics Ltd. is a global genomic diagnostics company based in Rehovot, Israel, specializing in the development and commercialization of diagnostic tests utilizing microRNA technologies. The company offers several key diagnostic solutions, including RosettaGX Cancer Origin, which identifies the primary site of metastatic cancer; mi-KIDNEY, a classification test for kidney tumors; RosettaGX Reveal, designed for diagnosing indeterminate thyroid fine-needle aspirate samples; and mi-LUNG, a diagnostic test for lung cancer. Additionally, Rosetta Genomics provides UroVysion, a urine-based assay for bladder carcinoma diagnosis and monitoring, along with FISH-based prognostic tests for prostate cancer and predictive tests for late-stage lung cancer. The company's diagnostic solutions are aimed at various medical specialists, including oncologists and urologists, to enhance patient care. Rosetta Genomics collaborates with institutions such as Max Planck Innovation GmbH and Meir Medical Center to further its research and development in the field of microRNAs. Founded in 2000, the company is committed to advancing personalized medicine through innovative diagnostic testing.